… that are associated with the adequacy of empirical antibiotic therapy and its impact in
mortality in a large cohort of patients with extended-spectrum β-lactamase (ESBL) - producing …

… In conclusion, empirical therapy with non-carbapenems is an effective method by which
to reduce the risk of development of carbapenem-resistant organisms in patients with UTIs …

… empirical therapy is … broad-spectrum empirical therapy early on for patients with severe
infections or those at risk of acquiring resistant organisms, but de-escalating to reduced-spectrum …

… empirical treatment should also cover ESBL-producing bacteria. However, it is unknown
how frequently initial treatment is truly empirical, … phenotypic extended spectrum beta-lactamase …

… show that empiric treatment with OAD was associated with a worse outcome compared with
carbapenems. This information allows more options to be considered for empiric therapy, at …

… empiric antimicrobial therapy employed and assess its effect on the outcome of patients
bacteremic with extended-spectrum beta-lactamase (… were treated with empiric therapy within the …

… empirical therapy was added to the model. The propensity score—the probability of receiving
carbapenem as empirical therapy… use of carbapenem as empirical therapy. The validity of …

… without appropriate empirical therapy (A), and of severe sepsis patients with and without
appropriate empirical therapy (B). The unbroken line represents appropriate empirical therapy, …

… changes between empiric therapy and definitive therapy regimens… Extended-spectrum
beta-lactamases in Klebsiella pneumoniae … prevalence of SHV- and CTX-M-type beta-lactamases …

… empiric therapy is believed to be critical in reducing mortality from bacteraemia [31]. As the
majority of our cohort received definitive carbapenem therapy, any … in the empiric treatment of …